Madison Vaccines Incorporated (MVI), a Madison, Wisconsin-based clinical stage biopharmaceutical company focused on advancing innovative therapies for prostate cancer, raised an initial close of an $8m in Series A financing.
The round was led by Venture Investors, LLC, with participation from Wisconsin Alumni Research Foundation (WARF), Venture Management, LLC (VM), the State of Wisconsin Investment Board (SWIB), and others.
The company intends to use the funds for the ongoing development of its pipeline, including completion of an expanded Phase 2 clinical trial for DNA vaccine MVI-816 in non-metastatic prostate cancer patients with rapidly rising PSA, before the need for surgical or chemical castration (androgen deprivation therapy or ADT).
Led by Richard Lesniewski, PhD, President, and Douglas McNeel, MD, PhD, Professor of Medicine at the University of Wisconsin-Madison, and Scientific Co-Founder, MVI develops therapeutic plasmid DNA vaccine products for patients with prostate cancer and a sensitivity test to identify those patients who will derive clinical benefit from these vaccines.
FinSMEs
13/01/2014